Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| 1 |
Microsoft
MSFT
|
$956M |
| 2 |
Ryanair
RYAAY
|
$678M |
| 3 |
Shopify
SHOP
|
$652M |
| 4 |
Sea Limited
SE
|
$499M |
| 5 |
Nu Holdings
NU
|
$330M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$2.25B |
| 2 |
Ginkgo Bioworks
DNA
|
$1.07B |
| 3 |
TSMC
TSM
|
$541M |
| 4 |
Tesla
TSLA
|
$428M |
| 5 |
Mercado Libre
MELI
|
$322M |
Sector Composition
| 1 | Consumer Discretionary | 32.31% |
| 2 | Technology | 26.39% |
| 3 | Communication Services | 14.86% |
| 4 | Healthcare | 11.39% |
| 5 | Financials | 6.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
BCE
BCE
$23.3B
| $1.09M | ﹤0.01% |
31,257
| – | – |
|
252
Varonis Systems
VRNS
$6.61B
| $1.05M | ﹤0.01% |
18,623
-1,181
| -6% | -$66.7K |
|
253
Novanta
NOVT
$4.19B
| $995K | ﹤0.01% |
5,561
-78
| -1% | -$14K |
|
254
Health Catalyst
HCAT
$239M
| $992K | ﹤0.01% |
121,855
-308,742
| -72% | -$2.51M |
|
255
Healthpeak Properties
DOC
$12.5B
| $936K | ﹤0.01% |
40,927
| – | – |
|
256
10x Genomics
TXG
$1.74B
| $912K | ﹤0.01% |
40,378
-2,701,775
| -99% | -$61M |
|
257
CarGurus
CARG
$3.43B
| $712K | ﹤0.01% |
23,693
-340
| -1% | -$10.2K |
|
258
Healthcare Realty
HR
$6.11B
| $698K | ﹤0.01% |
38,442
| – | – |
|
259
Calix
CALX
$3.88B
| $573K | ﹤0.01% |
14,765
-207
| -1% | -$8.03K |
|
260
Bandwidth Inc
BAND
$452M
| $525K | ﹤0.01% |
29,983
-429
| -1% | -$7.51K |
|
261
Xencor
XNCR
$610M
| $467K | ﹤0.01% |
23,204
-326
| -1% | -$6.56K |
|
|
MTLS
262
Materialise
MTLS
$302M
| $455K | ﹤0.01% |
83,119
| – | – |
|
263
Alector
ALEC
$262M
| $367K | ﹤0.01% |
78,835
-181,607
| -70% | -$846K |
|
264
Lyell Immunopharma
LYEL
$213M
| $196K | ﹤0.01% |
141,949
-378,049
| -73% | -$522K |
|
265
Spire Global
SPIR
$284M
| $132K | ﹤0.01% |
13,259
-94,996
| -88% | -$949K |
|
|
NCNA
266
NuCana
NCNA
$5.69M
| $84.4K | ﹤0.01% |
36,704
-109,656
| -75% | -$252K |
|
267
Teradyne
TER
$19.2B
| $38.8K | ﹤0.01% |
290
| – | – |
|
268
CRH
CRH
$74.7B
| $36.3K | ﹤0.01% |
391
+162
| +71% | +$15K |
|
269
Stantec
STN
$12.4B
| $24.2K | ﹤0.01% |
+300
| New | +$24.2K |
|
270
Unilever
UL
$156B
| $20.2K | ﹤0.01% |
311
+108
| +53% | +$7.02K |
|
271
Rio Tinto
RIO
$101B
| $20.1K | ﹤0.01% |
282
+161
| +133% | +$11.5K |
|
272
Intel
INTC
$106B
| $16.4K | ﹤0.01% |
700
| – | – |
|
273
AB InBev
BUD
$120B
| $6.63K | ﹤0.01% |
100
+1
| +1% | +$66 |
|
274
Novo Nordisk
NVO
$251B
| $6.31K | ﹤0.01% |
53
+9
| +20% | +$1.07K |
|
275
Genmab
GMAB
$15.9B
| $1.32K | ﹤0.01% |
54
| – | – |
|